CD90是一种潜在的癌症干细胞标志物和治疗靶点。

CD90 a potential cancer stem cell marker and a therapeutic target.

作者信息

Shaikh Muhammad Vaseem, Kala Manika, Nivsarkar Manish

机构信息

Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development Centre, S. G. Highway, Thaltej, Ahmedabad, Gujarat, India.

Faculty of Pharmacy, NIRMA University, Sarkhej-Gandhinagar Highway, Gota, Ahmedabad, Gujarat, India.

出版信息

Cancer Biomark. 2016;16(3):301-7. doi: 10.3233/CBM-160590.

DOI:10.3233/CBM-160590

PMID:27062695

Abstract

Cancer Stem Cells (CSCs) have been recently identified and their role in carcinogenesis has been ascertained. CSCs have been correlated with high relapse in certain cancers, multiple drug resistance against chemotherapy and metastasis. Several markers such as CD133, CD24, CD44, EpCAM, and CD26 have been identified to isolate and characterize CSCs. None of these markers or their combinations are universal in nature and can be used to isolate CSCs from all types of cancer. CD90 is one such marker whose expression has been extensively studied in recent years. CD90+ cells have been isolated from several types of tumors and shown to exhibit cardinal properties of CSCs such as proliferation, differentiation, spheroid formation, metastasis and ability to form tumor xenograft in immunodeficient mice. It is also found to be co-expressed with several other CSC markers. CD90 is therefore, suggested as a candidate marker as well as a potential therapeutic target for elimination of CSCs.

摘要

癌症干细胞（CSCs）最近已被识别，并且它们在致癌过程中的作用也已得到确定。癌症干细胞与某些癌症的高复发率、对化疗的多药耐药性以及转移有关。已经鉴定出几种标志物，如CD133、CD24、CD44、EpCAM和CD26，用于分离和表征癌症干细胞。这些标志物或其组合在本质上都不是通用的，不能用于从所有类型的癌症中分离癌症干细胞。CD90就是这样一种标志物，近年来对其表达进行了广泛研究。已从几种类型的肿瘤中分离出CD90+细胞，并显示出具有癌症干细胞的主要特性，如增殖、分化、球体形成、转移以及在免疫缺陷小鼠中形成肿瘤异种移植的能力。还发现它与其他几种癌症干细胞标志物共表达。因此，CD90被建议作为一种候选标志物以及消除癌症干细胞的潜在治疗靶点。